Corbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...

NORWOOD, Mass. (AP) — NORWOOD, Mass. (AP) — Corbus Pharmaceuticals Holdings Inc. (CRBP) on Tuesday reported a loss of $9.5 million in its fourth quarter. The Norwood, Massachusetts-based ...

Corbus Pharmaceuticals has a twelve month low of $6.38 and a twelve month high of $61.90. The company has a market capitalization of $82.70 million, a price-to-earnings ratio of -1.45 and a beta ...

Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) had its price target lowered by Jefferies Financial Group from $70.00 to $53.00 in a research report report published on Tuesday,Benzinga reports.

Jefferies lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $53 from $70 and keeps a Buy rating on the shares. The firm’s forecast for CRB-913 peak sales has been lowered to ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) yesterday and set a price target of $65.00. The company’s shares closed yesterday ...